The Uromigos Episode 158: ASCO GU 2022 PROpel Phase III Olaparib and Abiraterone in mCRPC

By The Uromigos - Last Updated: February 19, 2022

Dr. Fred Saad describes the results of the PROpel Phase III trial of abiraterone and olaparib versus abiraterone and placebo in patients with mCRPC.

Post Tags:Uromigos-ASCO GUUromigos-Prostate Cancer
Did you like this article?